|
CN104673897A
|
|
Method for determining biology activity of PD-1 pathway inhibitor
|
|
CN105272920A
|
|
Bendamustine hydrochloride mannitol ester and preparation method and application
|
|
CN105085541A
|
|
Method for preparing prasugrel analogue
|
|
CN105085405A
|
|
Preparation method and application of 4-[1-methyl-5-(2-chloroethyl-2-ethoxyl)amino-2-benzimidazolyl]butyric acid hydrochloride
|
|
CN105017193A
|
|
Preparation method of zanamivir impurity
|
|
CN104926816A
|
|
Tofacitinib analog and preparation method and application thereof
|
|
CN104673760A
|
|
Method for purifying prokaryotic cell expressed viroid particle
|
|
WO2014012505A1
|
|
Method for preparing vilazodone and intermediate thereof
|
|
CN104211808A
|
|
Preparation method of tumor necrosis factor related apoptosis induction ligand fusion protein
|
|
CN104211703A
|
|
Fused heterocycle compound as Bruton kinases inhibitor
|
|
CN104177363A
|
|
Bicyclic heterocyclic amine Hedgehog signal pathway inhibitor
|
|
CN104177338A
|
|
Bruton's kinase inhibitor
|
|
CN104116741A
|
|
Vilazodone hydrochloride composition and preparation method thereof
|
|
CN104043120A
|
|
Hepatitis b vaccine
|
|
CN103864770A
|
|
Pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors
|
|
WO2014075318A1
|
|
Pyrimidine compounds and use thereof
|
|
CN102977115A
|
|
Novel synthetic method of prasugrel free base
|
|
CN102964354A
|
|
Thienoimidazole-like derivatives and applications thereof
|
|
CN102898426A
|
|
Pyrazolopyridine derivatives for inhibiting activity of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase
|
|
CN103664911A
|
|
Method of preparing vilazodone and intermediate thereof
|
